The ABCB8 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human HT29 colon adenocarcinoma epithelial cells. This product features targeted disruption of the ABCB8 gene, which encodes a mitochondrial ATP-binding cassette transporter critical for mitochondrial iron homeostasis and maintenance of redox balance. As a polyclonal pool, these cells provide a genetically diverse loss-of-function model that avoids clonal selection biases, making them suitable for robust and reproducible screening in an intestinal epithelial context.
The HT29 host cell line, established from a 44-year-old female with colorectal adenocarcinoma, is a widely used in vitro model of intestinal epithelial biology. These cells display characteristic epithelial morphology and can differentiate into a polarized monolayer, recapitulating key features of the colonic epithelium. HT29 cells are particularly valuable for studying drug absorption, metabolism, and transport, as well as the metabolic adaptations of gastrointestinal cancer cells.
ABCB8 functions as a mitochondrial inner membrane transporter that exports iron from the mitochondrial matrix to the cytoplasm, a process essential for heme biosynthesis and iron?Csulfur cluster assembly. Its activity is transcriptionally regulated by upstream factors including HIF1A, NRF1, and PGC-1??, linking mitochondrial function to cellular oxygen and nutrient sensing. ABCB8 interacts with mitochondrial ferritin (FTMT) and mitoferrin (SLC25A37) to coordinate iron flux, and downstream it supports heme synthesis enzymes such as ALAS2 and the assembly of oxidative phosphorylation complexes. Disruption of ABCB8 impairs heme production, destabilizes iron?Csulfur cluster proteins, and sensitizes cells to oxidative stress, highlighting its central role in maintaining mitochondrial redox balance.
In the context of HT29 colorectal adenocarcinoma, ABCB8 knockout provides a powerful tool to investigate mechanisms of chemoresistance and mitochondrial dysfunction. ABCB8 expression is often altered in drug-resistant tumors, and its loss may lead to mitochondrial iron overload, mirroring pathological features of X-linked sideroblastic anemia. This model enables detailed study of how disrupted iron homeostasis impacts tumor cell viability, metabolic reprogramming, and response to oxidative insults, thereby uncovering potential therapeutic vulnerabilities.
Researchers can employ these cells for a broad range of applications, including probing mitochondrial iron metabolism, screening for modulators of heme biosynthesis, and evaluating cellular responses to oxidative stress. Assays such as western blotting for ABCB8 expression, iron quantification via ICP-MS, mitochondrial iron staining, heme measurement, oxygen consumption rate (OCR) analysis with Seahorse, and ROS detection are well-suited for this model. These applications facilitate mechanistic studies and drug discovery efforts targeting mitochondrial pathways in cancer and related disorders. For additional information, contact Ascent Research.
